Revenue rose 12.76% YoY to ¥11.10 billion and net profit surged 63.46% to ¥3.60 billion, driven by strong pharmaceutical and overseas sales, improved gross margins, and robust cash flow. Key initiatives included share repurchase, special dividends, and a major subsidiary merger.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.